ESTRO 2024 - Abstract Book

S1437

Clinical - Head & neck

ESTRO 2024

37 patients had post-treatment NavDx testing with a median time to follow-up, used for patients with NED, or time to recurrence of 12.24 months (range: 1.8 – 105.12). The post-treatment undetectable rate for patients following locoregional therapy with no metastasis was 97%. One patient had a detectable TTMV-DNA score of 64 and was found to have a recurrence upon further workup. One patient had an undetectable TTMV-DNA, but was found to have a recurrence four months after NavDx testing. The NPV for any recurrence or NED with post-treatment TTMV DNA was estimated for these 37 patients and is summarized in Table 2.

Five patients had metastatic or progressive disease prior to their first NavDx test. All 5 patients had detectable TTMV-DNA that predicted for recurrence of oropharynx cancer.

Conclusion: